PE20081164A1 - Nuevos compuestos 521 - Google Patents
Nuevos compuestos 521Info
- Publication number
- PE20081164A1 PE20081164A1 PE2007001564A PE2007001564A PE20081164A1 PE 20081164 A1 PE20081164 A1 PE 20081164A1 PE 2007001564 A PE2007001564 A PE 2007001564A PE 2007001564 A PE2007001564 A PE 2007001564A PE 20081164 A1 PE20081164 A1 PE 20081164A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- phenyl
- group
- substituted
- new compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- -1 ALCOXY C1-C6 Inorganic materials 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical class N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001450 anions Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 FORMAN UN ANILLO ALIFATICO DE 7 MIEMBROS SUSTITUIDO O NO POR HALOGENO, ALCOXI C1-C6, NH2, OH, ENTRE OTROS; R3 ES FENILO, ANILLO HETEROARILO DE 5 A 6 MIEMBROS, SUSTITUIDOS O NO POR NITRO, SH, CIANO, ENTRE OTROS; R4 ES II, IIIa O IIIb; Y ES -CH2-, -CH2CH2-, -CH2CH2CH2-; a Y b SON CADA UNO 1-2; z ES -CH2-; R5 ES IV; w ES 0-1; R6 ES ALQUILENO C1-C4; Q ES O, -C(O)O-, ETINILENO, ENTRE OTROS; y ES 0-1; R7 ES UN GRUPO CICLICO O UN GRUPO C1-C4 ALQUILOSUSTITUIDOS O NO; X ES UN ANION DE UN ACIDO MONO O POLIVALENTE. UN COMPUESTO PREFERIDO ES: (3R)-1-METIL-3-{[(1-FENILCICLOHEPTIL)CARBONIL]OXI}-1-AZONIABICICLO[2,2,2]OCTANO X. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN ANTAGONISTA MUSCARINICO, UTIL EN EL TRATAMIENTO DE ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86566706P | 2006-11-14 | 2006-11-14 | |
| US86938406P | 2006-12-11 | 2006-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081164A1 true PE20081164A1 (es) | 2008-10-31 |
Family
ID=39048793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001564A PE20081164A1 (es) | 2006-11-14 | 2007-11-13 | Nuevos compuestos 521 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8207193B2 (es) |
| EP (2) | EP2256117A1 (es) |
| JP (1) | JP4904402B2 (es) |
| KR (1) | KR20090078828A (es) |
| AR (1) | AR063804A1 (es) |
| AT (1) | ATE496916T1 (es) |
| AU (1) | AU2007321019B2 (es) |
| BR (1) | BRPI0718750A2 (es) |
| CA (1) | CA2669326A1 (es) |
| CL (1) | CL2007003260A1 (es) |
| CO (1) | CO6160312A2 (es) |
| CY (1) | CY1111351T1 (es) |
| DE (1) | DE602007012300D1 (es) |
| DK (1) | DK2094694T3 (es) |
| EC (1) | ECSP099338A (es) |
| HR (1) | HRP20110178T1 (es) |
| IL (1) | IL198314A (es) |
| MX (1) | MX2009004780A (es) |
| MY (1) | MY148392A (es) |
| NO (1) | NO20092224L (es) |
| NZ (1) | NZ576679A (es) |
| PE (1) | PE20081164A1 (es) |
| PL (1) | PL2094694T3 (es) |
| PT (1) | PT2094694E (es) |
| RS (1) | RS51650B (es) |
| RU (1) | RU2456286C2 (es) |
| SA (1) | SA07280616B1 (es) |
| TW (1) | TW200825084A (es) |
| WO (1) | WO2008059245A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657915A1 (en) * | 2006-07-21 | 2008-01-24 | Mars, Incorporated | Improvement of arginase levels/activity |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| WO2009138707A1 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
| GB0808709D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New combination 295 |
| GB0808708D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| EP2315589A4 (en) * | 2008-05-13 | 2013-09-11 | Astrazeneca Ab | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST |
| GB0811099D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination 376 |
| UY31920A (es) * | 2008-06-20 | 2010-01-29 | Astrazeneca Ab | Nueva combinacion-408 |
| WO2010008341A1 (en) * | 2008-07-16 | 2010-01-21 | Astrazeneca Ab | A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist |
| GB0814729D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| EP2433124B1 (en) * | 2009-05-19 | 2017-03-01 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| KR20130111968A (ko) * | 2010-06-22 | 2013-10-11 | 키에시 파르마슈티시 엣스. 피. 에이. | 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물 |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| ES2661393T3 (es) | 2012-04-30 | 2018-03-28 | Biothera, Inc. | Preparación inmunoterapéutica de beta glucano |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) * | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL62140C (es) * | 1942-12-16 | |||
| DE2104179C3 (de) | 1971-01-29 | 1980-10-02 | Knoll Ag, 6700 Ludwigshafen | exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel |
| FR2155927A1 (en) | 1971-10-15 | 1973-05-25 | Synthelabo | 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity |
| FR2168881A1 (en) | 1972-01-25 | 1973-09-07 | Synthelabo | Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics |
| FR2208649A1 (en) | 1972-12-01 | 1974-06-28 | Synthelabo | 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| IL77458A (en) | 1985-01-14 | 1990-07-26 | Eisai Co Ltd | Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| SE9003057D0 (sv) | 1990-09-26 | 1990-09-26 | Astra Ab | New process |
| WO1992015590A1 (en) | 1991-03-07 | 1992-09-17 | G.D. Searle & Co. | New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents |
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| US6124354A (en) | 1996-07-29 | 2000-09-26 | Pharmacia & Upjohn Ab | Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ES2407135T3 (es) | 1996-11-11 | 2013-06-11 | Meda Pharma Gmbh & Co. Kg | Uso de (3S,2'R)-glicopirronio como medicamento |
| US6613795B2 (en) * | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| KR20030022264A (ko) | 2000-07-07 | 2003-03-15 | 앤지오젠 파마슈티칼스 리미티드 | 신생 혈관 형성 억제제인 콜치놀 유도체 |
| AU2002228015B2 (en) * | 2000-12-22 | 2007-08-23 | Almirall, S.A. | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| UA75626C2 (en) | 2000-12-28 | 2006-05-15 | Almirall Prodesfarma Ag | Quinuclidine derivatives and medicinal compositions containing the same |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| JP2004532874A (ja) | 2001-04-03 | 2004-10-28 | アリックス セラピューティクス | 抗コリン作用性化合物および使用法 |
| US7291608B2 (en) | 2001-04-30 | 2007-11-06 | Glaxo Group Limited | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| DE10216333A1 (de) | 2002-04-13 | 2003-10-30 | Boehringer Ingelheim Pharma | Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| CA2499314C (en) | 2002-10-11 | 2010-08-24 | Pfizer Inc. | Indole derivatives as beta-2 agonists |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| PE20050231A1 (es) | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| EP1684767A1 (en) | 2003-11-03 | 2006-08-02 | Norton Healthcare Limited | Soft steroid compositions for use in dry powder inhalers |
| US20080027094A1 (en) | 2004-08-30 | 2008-01-31 | Ono Pharmaceutical Co., Ltd. | Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient |
| US20090105221A1 (en) | 2004-09-29 | 2009-04-23 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| CA2584413A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| TW200722418A (en) | 2005-04-20 | 2007-06-16 | Astrazeneca Ab | Novel compounds |
| CA2617127A1 (en) | 2005-08-01 | 2007-02-08 | Astrazeneca Ab | Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases. |
| TW200738635A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| CA2618089A1 (en) | 2005-08-08 | 2007-02-15 | Argenta Discovery Ltd. | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| US20090182033A1 (en) | 2005-12-16 | 2009-07-16 | Argenta Discovery Ltd. | Cyclic Amine Derivatives and Their Uses |
| WO2007123465A1 (en) | 2006-04-24 | 2007-11-01 | Astrazeneca Ab | New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder |
| JP2009543860A (ja) | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
| GB0702384D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Chemical compounds |
| WO2008017827A2 (en) | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
| JP2010501533A (ja) | 2006-08-21 | 2010-01-21 | アージェンタ ディスカバリー リミテッド | Ｍ３レセプター調節物質として有用な窒素含有複素環化合物 |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| WO2008059239A1 (en) | 2006-11-14 | 2008-05-22 | Astrazeneca Ab | Novel compounds 514 |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| WO2008075006A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd) |
| CA2672446A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| WO2008096094A1 (en) | 2007-02-06 | 2008-08-14 | Argenta Discovery Ltd. | Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators |
| WO2008096093A1 (en) | 2007-02-06 | 2008-08-14 | Argenta Discovery Ltd. | Oxazole and thiazole derivatives and their uses |
| GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| GB0702382D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New salt |
| US7846955B2 (en) | 2007-02-07 | 2010-12-07 | Astrazeneca Ab | Salt |
| GB0702385D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702416D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702414D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Oxazole and thiazole derivatives and their uses 2 |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| CN101657452A (zh) | 2007-02-15 | 2010-02-24 | 阿金塔探索有限公司 | 作为m3毒蕈碱性受体的杂环衍生物 |
| GB0704000D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
| WO2008149053A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Ltd. | Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use |
| WO2008149110A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
| WO2009098453A1 (en) | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists |
| WO2009098455A1 (en) | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease |
| PT2242759E (pt) | 2008-02-06 | 2012-12-17 | Astrazeneca Ab | Compostos |
| WO2009138707A1 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
| GB0808707D0 (en) | 2008-05-13 | 2008-06-18 | Argenta Discovery Ltd | New compounds 275 |
| GB0808709D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New combination 295 |
| GB0808708D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| EP2315589A4 (en) | 2008-05-13 | 2013-09-11 | Astrazeneca Ab | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST |
| GB0811100D0 (en) | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
| GB0811099D0 (en) | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination 376 |
| WO2009153536A1 (en) | 2008-06-17 | 2009-12-23 | Argenta Discovery Limited | 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| WO2010018352A1 (en) | 2008-08-12 | 2010-02-18 | Argenta Discovery Limited | Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated |
| GB0814729D0 (en) | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| WO2010019099A1 (en) | 2008-08-12 | 2010-02-18 | Astrazeneca Ab | 2-hydroxy-ethanesulfonate salt |
| GB0814728D0 (en) | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
-
2007
- 2007-11-02 TW TW096141387A patent/TW200825084A/zh unknown
- 2007-11-12 SA SA07280616A patent/SA07280616B1/ar unknown
- 2007-11-13 KR KR1020097009772A patent/KR20090078828A/ko not_active Ceased
- 2007-11-13 PT PT07824574T patent/PT2094694E/pt unknown
- 2007-11-13 WO PCT/GB2007/004350 patent/WO2008059245A1/en not_active Ceased
- 2007-11-13 JP JP2009536788A patent/JP4904402B2/ja not_active Expired - Fee Related
- 2007-11-13 US US12/514,509 patent/US8207193B2/en not_active Expired - Fee Related
- 2007-11-13 CA CA002669326A patent/CA2669326A1/en not_active Abandoned
- 2007-11-13 EP EP10175910A patent/EP2256117A1/en not_active Withdrawn
- 2007-11-13 RU RU2009115829/04A patent/RU2456286C2/ru not_active IP Right Cessation
- 2007-11-13 MX MX2009004780A patent/MX2009004780A/es active IP Right Grant
- 2007-11-13 MY MYPI20091925A patent/MY148392A/en unknown
- 2007-11-13 HR HR20110178T patent/HRP20110178T1/hr unknown
- 2007-11-13 DE DE602007012300T patent/DE602007012300D1/de active Active
- 2007-11-13 PE PE2007001564A patent/PE20081164A1/es not_active Application Discontinuation
- 2007-11-13 NZ NZ576679A patent/NZ576679A/en not_active IP Right Cessation
- 2007-11-13 AR ARP070105051A patent/AR063804A1/es not_active Application Discontinuation
- 2007-11-13 CL CL200703260A patent/CL2007003260A1/es unknown
- 2007-11-13 DK DK07824574.3T patent/DK2094694T3/da active
- 2007-11-13 BR BRPI0718750-5A patent/BRPI0718750A2/pt not_active IP Right Cessation
- 2007-11-13 AT AT07824574T patent/ATE496916T1/de active
- 2007-11-13 PL PL07824574T patent/PL2094694T3/pl unknown
- 2007-11-13 RS RS20110126A patent/RS51650B/sr unknown
- 2007-11-13 EP EP07824574A patent/EP2094694B1/en active Active
- 2007-11-13 AU AU2007321019A patent/AU2007321019B2/en not_active Ceased
-
2009
- 2009-04-23 IL IL198314A patent/IL198314A/en not_active IP Right Cessation
- 2009-04-24 CO CO09041752A patent/CO6160312A2/es unknown
- 2009-05-15 EC EC2009009338A patent/ECSP099338A/es unknown
- 2009-06-09 NO NO20092224A patent/NO20092224L/no not_active Application Discontinuation
-
2011
- 2011-03-22 CY CY20111100315T patent/CY1111351T1/el unknown
-
2012
- 2012-05-15 US US13/471,912 patent/US20130005695A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081164A1 (es) | Nuevos compuestos 521 | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
| PE20060921A1 (es) | Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales | |
| PE20080077A1 (es) | Derivados de sulfonilfenilo como antagonistas del receptor de il-8 | |
| PE20080769A1 (es) | Derivados de biaril-sulfonamida | |
| BR0313341A (pt) | Método para a preparação de uma oxazinona fundida e método para a preparação de um composto de fórmula iii | |
| CO6140053A2 (es) | Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20060186A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion asi como su uso como medicamento | |
| BRPI0406762A (pt) | Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça | |
| AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
| NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| BRPI0511933B8 (pt) | derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica | |
| RU2009146124A (ru) | Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk | |
| BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| PE20060620A1 (es) | Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1 | |
| AR041563A1 (es) | Derivados de quinazolinona con actividad antagonista del receptor vanilloide humano tipo 1 (vr1) utiles como agentes antihiperalgesicos | |
| ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |